Ultragenyx Pharmaceutical (RARE) Tax Provisions (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Tax Provisions data on file, last reported at $1.0 million in Q1 2026.

• On a quarterly basis, Tax Provisions changed 0.0% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $3.7 million, a 44.99% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 100.0% from the prior year.
• Tax Provisions for Q1 2026 stood at $1.0 million, up from $870000.0 in the prior quarter.
• Over the last five years, Tax Provisions for RARE reached as high as $6.3 million in Q3 2022 and fell as low as -$3.9 million in Q4 2023.
• Historically, Tax Provisions has averaged $707411.8 across 5 years, with a median of $650000.0 in 2023.
• Across the five-year window, Tax Provisions surged 3354.4% in 2022 and tumbled 2151.32% in 2023, its largest moves.
• Year by year, Tax Provisions stood at $189000.0 in 2022, then tumbled by 2151.32% to -$3.9 million in 2023, then soared by 109.9% to $384000.0 in 2024, then soared by 126.56% to $870000.0 in 2025, then advanced by 14.94% to $1.0 million in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were $1.0 million in Q1 2026, $870000.0 in Q4 2025, and $873000.0 in Q3 2025.